Overview development of TAK-003 - Live-attenuated tetravalent dengue vaccine

Host : Professor Thomas Preiss & Professor Ian Cockburn

Biography

Dr. Eckhardt Petri is a Senior Director Global Medical Affairs, currently responsible for Dengue (Non endemic markets) and for Zika. Before that, he has been the Global Medical Affairs Lead for a Norovirus Vaccine in development and leading the European/Canadian (EuCan) Medical Affairs activities for Takeda’s Vaccines Business Unit. He graduated a diploma in human biology from Philipps-University, Marburg in 1993. Thereafter, he took up residency at the Eberhard-Karls-University Tuebingen, where in 1997 he received a PhD in the field of immuno-oncology. Dr.Eckhardt also holds a Master of Health Business Administration (MHBA), received by the Friedrich-Alexander University in Erlangen-Nuremberg. Prior to joining Takeda, Dr. Eckhardt Petri worked the first third of his career as a product manager within biotech & diagnostics industry and thereafter served almost 18 years in Medical Affairs for Vaccines. During his career, he has been contributing to several new vaccine launches in Europe and in North America, as well as in the introduction of an adjuvanted influenza vaccine in the USA.

He has been leading (sero-)epidemiological studies, e.g., for Tick-Borne Encephalitis and Japanese Encephalitis. Further to that, he has been involved in diverse health economics projects in the field of influenza vaccines. In one of his previous roles as a Regional Medical Affairs Head, Dr. Eckhardt has been responsible for establishing a Medical Affairs/Market Access organisation for a newly created vaccine company (Seqirus) in 2015-2017. In his previous positions, Dr. Eckhardt also has medically supported pandemic preparation projects, which included contract discussions with European and Asian Health ministries and supranational Public Health organisations.